دورية أكاديمية
Diacerein-Loaded Hyaluosomes as a Dual-Function Platform for Osteoarthritis Management via Intra-Articular Injection: In Vitro Characterization and In Vivo Assessment in a Rat Model.
| العنوان: | Diacerein-Loaded Hyaluosomes as a Dual-Function Platform for Osteoarthritis Management via Intra-Articular Injection: In Vitro Characterization and In Vivo Assessment in a Rat Model. |
|---|---|
| المؤلفون: | Eladawy NO; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt., Morsi NM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt., Shamma RN; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. |
| المصدر: | Pharmaceutics [Pharmaceutics] 2021 May 21; Vol. 13 (6). Date of Electronic Publication: 2021 May 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | The application of intra-articular injections in osteoarthritis management has gained great attention lately. In this work, novel intra-articular injectable hyaluronic acid gel-core vesicles (hyaluosomes) loaded with diacerein (DCN), a structural modifying osteoarthritis drug, were developed. A full factorial design was employed to study the effect of different formulation parameters on the drug entrapment efficiency, particle size, and zeta potential. Results showed that the prepared optimized DCN- loaded hyaluosomes were able to achieve high entrapment (90.7%) with a small size (310 nm). The morphology of the optimized hyaluosomes was further examined using TEM, and revealed spherical shaped vesicles with hyaluronic acid in the core. Furthermore, the ability of the prepared DCN-loaded hyaluosomes to improve the in vivo inflammatory condition, and deterioration of cartilage in rats (injected with antigen to induce arthritis) following intra-articular injection was assessed, and revealed superior function on preventing cartilage damage, and inflammation. The inflammatory activity assessed by measuring the rat's plasma TNF-α and IL-1b levels, revealed significant elevation in the untreated group as compared to the treated groups. The obtained results show that the prepared DCN-loaded hyaluosomes would represent a step forward in the design of novel intra articular injection for management of osteoarthritis. |
| References: | Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. (PMID: 26806184) Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. (PMID: 20816981) Int J Nanomedicine. 2020 Nov 12;15:8893-8910. (PMID: 33209023) Int J Pharm. 2010 Sep 15;397(1-2):164-72. (PMID: 20599487) Int J Pharm. 2016 Dec 30;515(1-2):657-668. (PMID: 27989826) Am J Manag Care. 2009 Sep;15(8 Suppl):S223-9. (PMID: 19817508) Clin Pharmacokinet. 1998 Nov;35(5):347-59. (PMID: 9839088) Pharm Res. 2015 Sep;32(9):2901-11. (PMID: 25777613) Exp Ther Med. 2018 Jan;15(1):400-406. (PMID: 29387194) Int J Pharm. 2015 Jul 25;490(1-2):146-54. (PMID: 26002566) Osteoarthritis Cartilage. 2020 Mar;28(3):242-248. (PMID: 31945457) BMC Musculoskelet Disord. 2015 Oct 26;16:321. (PMID: 26503103) AAPS PharmSciTech. 2019 Feb 8;20(3):104. (PMID: 30737611) J Dairy Sci. 2018 Nov;101(11):9680-9692. (PMID: 30197146) Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53. (PMID: 23973124) Pharm Dev Technol. 2019 Oct;24(8):947-953. (PMID: 30676142) Carbohydr Polym. 2018 Feb 1;181:1194-1205. (PMID: 29253949) J Liposome Res. 2016;26(1):57-68. (PMID: 25853339) Osteoarthritis Cartilage. 2015 Nov;23(11):1906-14. (PMID: 26521736) Drug Deliv Transl Res. 2016 Aug;6(4):342-53. (PMID: 27371394) Pharmaceutics. 2020 Aug 12;12(8):. (PMID: 32806740) Adv Drug Deliv Rev. 2006 May 20;58(2):226-42. (PMID: 16574267) J Orthop Res. 1992 Jan;10(1):58-61. (PMID: 1727936) Drug Des Devel Ther. 2019 Jun 28;13:2043-2055. (PMID: 31388296) Int J Pharm. 2006 Aug 31;320(1-2):37-44. (PMID: 16707237) Drug Deliv. 2018 Nov;25(1):815-826. (PMID: 29557244) Clin Transl Med. 2018 Feb 16;7(1):6. (PMID: 29450666) Tissue Eng Part B Rev. 2010 Feb;16(1):81-92. (PMID: 19943805) Asian J Pharm Sci. 2018 Sep;13(5):498-504. (PMID: 32104423) Int J Nanomedicine. 2019 Jul 05;14:4961-4974. (PMID: 31308666) J Drug Target. 2018 Aug;26(7):563-575. (PMID: 29073792) Front Pharmacol. 2013 Nov 21;4:143. (PMID: 24319430) J Chromatogr A. 2008 Mar 21;1185(1):71-7. (PMID: 18272158) Int J Pharm. 2020 Jun 15;583:119378. (PMID: 32360505) Int J Mol Sci. 2019 Sep 23;20(19):. (PMID: 31547569) Int J Pharm. 2015;486(1-2):88-98. (PMID: 25818063) Int J Biol Macromol. 2017 Apr;97:642-653. (PMID: 28109811) Drug Des Devel Ther. 2018 Jun 27;12:1917-1930. (PMID: 29983546) Drugs Aging. 2016 Feb;33(2):75-85. (PMID: 26849131) J Control Release. 2013 Dec 28;172(3):1142-50. (PMID: 24103813) Exp Biol Med (Maywood). 2019 Apr;244(6):433-444. (PMID: 29996674) Arthritis Res Ther. 2003;5(2):54-67. (PMID: 12718745) |
| فهرسة مساهمة: | Keywords: diacerein; hyaluronic acid; intra-articular injection; osteoarthritis |
| تواريخ الأحداث: | Date Created: 20210602 Latest Revision: 20210714 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8223785 |
| DOI: | 10.3390/pharmaceutics13060765 |
| PMID: | 34063749 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!